Vasoactive Intestinal Polypeptide
RELIEF THERAPEUTICS HOLDING SA Announces Plans to Test Aviptadil for Treatment of COVID-induced Acute Respiratory Distress Syndrome
The phase 2 clinical trial of RLF-100 (Aviptadil) is being coordinated with the Senior Leadership of the Government of Israel for the treatment of Acute Respiratory Distress Syndrome in patients with COVID-19 infection. The trial is being coordinated by Prof. Jonathan Javitt, MD, MPH, acting Chairman of the Scientific Advisory Board of Relief in coordination with Dr. Miki Halberthal, MD, CEO of the Rambam Healthcare Campus and Dr. Boaz Lev, head of Israel’s COVID task force and former Director-General of Israel’s Ministry of Health.
